rais forecast new test
potenti leverag broad panther base
expect ex-covid test
pre-announce link holx revenu organ
growth februari gross margin remain flat yoy
our/street cyno divestur benefit off-set covid impact
opm increas start cut cost late march ep
decreas yoy partial due higher effect tax rate
previous withdrawn guidanc management note april sale
ex-covid test revenu suggest similar trend core breast
diagnost surgic skelet segment
respect expect busi rebound believ
women health may recov faster rel routine/wel visit
covid test add could sustain
much call focus holx molecular diagnost mdx test
test launch next week fda eua submiss also plan initi bolu
ruo test kit ship holx mdx test ran panther fusion
system unit us new test run holx larger
scalabl instal base panther unit us
world-wide new test price slightli panther fusion
ramp product capac tests/week late may covid test
could add largest instal base high-
throughput mdx platform test us
roch coba unit bode well share gain
rais estim po test tailwind
await vaccin see high level mdx test sustain
rais sale ep est
upsid potenti demand greater expect reiter buy rate
rais po prior ep believ higher multipl
warrant given critic role mdx test vendor
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
core mammographi diagnost
busi deliv solid perform
believ steadier
foot organ growth upsid due
expand offer breast health strength
molecular diagnost mdx busi cynosur
cyno busi divest thu longer
controversi stock may allow
stock rerat investor focu
po base approxim calendar ep estim
roughli in-lin three-year histor averag compani
diagnost med-tech peer multipl believ multipl justifi
given organ growth profil breast molecular diagnost
upsid risk po faster growth core diagnost mammographi
gynecolog surgeri end market synergi addit tuck-in deal
downsid risk po competit pressur slower uptak reimburs
new product market challeng relat pandem unfavor
chang clinic practic guidelin manag departur regulatori risk
faster declin legaci busi
ivi herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
